Table 1.
Clinical and laboratory findings for 42 patients with ankylosing spondylitis treated with infliximab
| Finding | BASDAI | BASMI | BASFI | PatGA | PhysGA | NRS-P | ESR (mm/h) | CRP (mg/l) |
| At time point 1a | ||||||||
| Mean ± SD | 2.5 ± 1.8** | 2.7 ± 2.0* | 2.9 ± 2.4** | 2.6 ± 1.5** | 2.6 ± 2.1** | 2.6 ± 2.1** | 10.5 ± 7.3** | 3.1 ± 4.2** |
| Median | 2.4 | 2.0 | 2.5 | 4.0 | 2.0 | 2.0 | 8.0 | 1.1 |
| Range | 0.0 - 6.8 | 0.0 - 7.0 | 0.0 - 8.3 | 0.0 - 8.0 | 0.0 - 4.0 | 0.0 - 7.0 | 2.0 - 32.0 | 0.0 - 19.0 |
| At time point 2a | ||||||||
| Mean ± SD | 6.1 ± 1.4** | 3.2 ± 2.2* | 5.8 ± 1.8** | 6.9 ± 2.1** | 7.0 ± 1.5** | 7.1 ± 1.7** | 31.5 ± 29.7** | 20.7 ± 23.7** |
| Median | 6.2 | 3.0 | 5.7 | 7.0 | 7.0 | 7.0 | 23.0 | 14.0 |
| Range | 4.0 - 9.2 | 0.0 - 9.0 | 1.2 - 9.1 | 4.0 - 10.0 | 4.0 - 10.0 | 0.0 - 10.0 | 4.0 - 150.0 | 0.3 - 126.0 |
| Change between time points 1 and 2 | ||||||||
| Mean ± SD | 3.6 ± 1.7 | 0.5 ± 1.5 | 2.9 ± 2.0 | 4.3 ± 1.9 | 4.4 ± 1.8 | 4.5 ± 2.2 | 21.0 ± 29.7 | 17.6 ± 23.4 |
| Median | 3.6 | 0.5 | 2.5 | 4.0 | 4.0 | 4.0 | 12.0 | 11.5 |
| Range | -1.2 - 6.7 | -4.0 - 3.0 | -0.5 - 7.8 | -2.0 - 8.0 | -2.0 - 8.0 | -1.0 - 8.0 | -6.0 - 146.0 | -6.3 - 123.0 |
aTime point 1 is the time point at which infliximab treatment was discontinued; time point 2 is that when retreatment began. *P < 0.05, **P < 0.001, when means at time points 1 and 2 are compared. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NRS-P, numerical rating scale for pain; PatGA, patient's global assessment; PhysGA, physician's global assessment; SD, standard deviation.